The Rubicon Research IPO opens on October 9, 2025, and closes on October 13, 2025. The Rubicon Research IPO is a book-built issue. The company will raise approximately ₹1,377.50 crore through the IPO, comprising a fresh issue of shares worth ₹500 crore and an offer for sale of 1,80,92,762 equity shares with a face value of ₹1.
The price band for the Rubicon Research IPO is ₹461 to ₹485 per share. The retail share is 10%, QIBs 75%, and HNIs 15%. The Rubicon Research IPO will be listed on the BSE and NSE on October 16, 2025. The allotment for the Rubicon Research IPO will take place on October 14, 2025.
The company reported revenue of ₹1,296.22 crore in 2025, compared to ₹872.39 crore in 2024. The company reported a profit of ₹134.36 crore in 2025, compared to ₹91.01 crore in 2024. Based on the financials, IPO investors should invest in the IPO for the long term.
Rubicon Research IPO Details
| IPO Open Date | October 9, 2025 |
| IPO Close Date | October 13, 2025 |
| Face Value | ₹1 Per Equity Share |
| IPO Price Band | ₹461 to ₹485 Per Share |
| Issue Size | Approx ₹1,377.50 Crores |
| Fresh Issue | Approx ₹500 Crores |
| Offer for Sale: | Approx 1,80,92,762 Equity Shares |
| Issue Type | Book Built Issue |
| IPO Listing | BSE, NSE |
| DRHP Draft Prospectus |  |
| RHP Draft Prospectus | |
Rubicon Research IPO Review & Key Points
- Review:
Rubicon Research IPO Market Lot
The Rubicon Research IPO minimum market lot is 30 shares with ₹14,550 application amount. The retail investors can apply up-to 13 lots with 390 shares of ₹1,89,150 amount.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 1 | 30 | ₹14,550 |
| Retail Maximum | 13 | 390 | ₹1,89,150 |
| S-HNI Minimum | 14 | 420 | ₹2,03,700 |
| S-HNI Maximum | 68 | 2,040 | ₹9,89,400 |
| B-HNI Minimum | 69 | 2,070 | ₹10,03,950 |
IPO Reservation
| Investor Category | Share Offered | -% Shares |
| Anchor Investor | – Shares | -% |
| QIB (Ex. Anchor) | – Shares | 75% |
| NII Shares Offered | – Shares | 15% |
| Retail Shares Offered | – Shares | 10% |
Rubicon Research IPO Anchor Investors
| Anchor Bidding Date | October 8, 2025 |
| Anchor Investors List | |
| Shares Offered | [.] Shares |
| Anchor Size | [.] Cr. |
| lock-in period end date 50% shares (30 Days) | November 13, 2025 |
| lock-in period end date 50% shares (90 Days) | January 12, 2025 |
Rubicon Research IPO Dates
The Rubicon Research IPO date is October 9 and the close date is October 13. The Rubicon Research IPO allotment will be finalized on October 14 and the IPO listing on October 16.
| IPO Open Date: | October 9, 2025 |
| IPO Close Date: | October 13, 2025 |
| Basis of Allotment: | October 14, 2025 |
| Refunds: | October 15, 2025 |
| Credit to Demat Account: | October 15, 2025 |
| IPO Listing Date: | October 16, 2025 |
| IPO Bidding Cut-off Time: | October 13, 2025 – 5 PM |
Promoters and Holding Pattern
The promoters of the company are General Atlantic Singapore RR Pte. Ltd., Pratibha Pilgaonkar, Sudhir Dhirendra Pilgaonkar, Parag Suganchand Sancheti, Surabhi Parag Sancheti and Sumant Sudhir Pilgaonkar.
| Particular | Shares | % Share |
| Promoter Holding Pre Issue | 15,44,37,251 | 77.67% |
| Promoter Holding Post Issue | 16,47,46,529 | 72.80% |
Objects of the Issue & Utilisation of proceeds
| Purpose | Crores |
| Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by the Company | 310 |
| Funding inorganic growth through unidentified acquisitions and other strategic initiatives and General corporate purposes |
About Rubicon Research IPO
To be updated soon
Rubicon Research IPO Company Financial Report
Amount ₹ in Crores
| Period Ended | Revenue | Expense | PAT | Assets |
| 2023 | ₹419.00 | ₹430.05 | ₹16.89 | ₹749.70 |
| 2024 | ₹872.39 | ₹769.53 | ₹91.01 | ₹1,109.49 |
| 2025 | ₹1,296.22 | ₹1,101.70 | ₹134.36 | ₹1,451.43 |
| June 2025 | ₹356.95 | ₹297.39 | ₹43.30 | ₹1,647.60 |
Rubicon Research IPO Valuation – FY2025
Check Rubicon Research IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | 29.02% |
| ROCE: | 26.45% |
| EBITDA Margin: | 20.67% |
| PAT Margin: | 10.37% |
| Debt to equity ratio: | 0.51 |
| Earning Per Share (EPS): | ₹8.82 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 29.02% |
| Net Asset Value (NAV): | ₹35.53 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Sun Pharmaceutical Industries Limited | 45.60 | 34.98 | 16.16% | 300.99 | 52,578.44 Cr. |
| Aurobindo Pharma Limited | 59.81 | 18.12 | 11.15% | 560.22 | 31,723.73 Cr. |
| Zydus Lifesciences Limited | 44.97 | 21.83 | 21.34% | 238.05 | 23,241.50 Cr. |
| Strides Pharma Science Limited | 44.05 | 18.72 | 17.51% | 277.34 | 4,565.34 Cr. |
| Dr. Reddy’s Laboratories Limited | 67.89 | 18.05 | 18.53% | 402.78 | 32,643.90 Cr. |
| Alembic Pharmaceuticals Limited | 29.68 | 30.33 | 11.63% | 264.09 | 6,672.08 Cr. |
| Lupin Limited | 71.95 | 26.64 | 21.00% | 377.18 | 22,707.90 Cr. |